{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:37:27Z","timestamp":1790775447441,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/leu.2017.138","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T04:41:27Z","timestamp":1497588087000},"page":"2443-2448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":318,"title":["Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"S K","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Nahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"M","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E M","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M V","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E K","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N W C J","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-4548","authenticated-orcid":false,"given":"M","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Mellqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Z","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Z","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"K","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P R","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Shustik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W J","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H S","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rosinol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J S","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B G M","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"BFleu2017138_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122\u20131128.","journal-title":"Leukemia"},{"key":"BFleu2017138_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.13537","volume":"171","author":"D Pulte","year":"2015","unstructured":"Pulte D, Jansen L, Castro FA, Emrich K, Katalinic A, Holleczek B et al. Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. Br J Haematol 2015; 171: 189\u2013196.","journal-title":"Br J Haematol"},{"key":"BFleu2017138_CR3","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1038\/bcj.2015.79","volume":"5","author":"S Ozaki","year":"2015","unstructured":"Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 2015; 5: e349.","journal-title":"Blood Cancer J"},{"key":"BFleu2017138_CR4","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1038\/bcj.2016.15","volume":"6","author":"M Binder","year":"2016","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J 2016; 6: e401.","journal-title":"Blood Cancer J"},{"key":"BFleu2017138_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467\u2013472.","journal-title":"Nature"},{"key":"BFleu2017138_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067\u20131076.","journal-title":"Blood"},{"key":"BFleu2017138_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91\u2013101.","journal-title":"Cancer Cell"},{"key":"BFleu2017138_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27\u201338.","journal-title":"Lancet Oncol"},{"key":"BFleu2017138_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142\u2013152.","journal-title":"N Engl J Med"},{"key":"BFleu2017138_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374: 1621\u20131634.","journal-title":"N Engl J Med"},{"key":"BFleu2017138_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","volume":"128","author":"SZ Usmani","year":"2016","unstructured":"Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 2016; 128: 37\u201344.","journal-title":"Blood"},{"key":"BFleu2017138_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551\u20131560.","journal-title":"Lancet"},{"key":"BFleu2017138_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621\u2013631.","journal-title":"N Engl J Med"},{"key":"BFleu2017138_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207\u20131219.","journal-title":"N Engl J Med"},{"key":"BFleu2017138_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149\u2013157.","journal-title":"Leukemia"},{"key":"BFleu2017138_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867\u2013874.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2017138_CR17","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691\u20134695.","journal-title":"Blood"},{"key":"BFleu2017138_CR18","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1038\/bcj.2015.60","volume":"5","author":"SK Kumar","year":"2015","unstructured":"Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015; 5: e338.","journal-title":"Blood Cancer J"},{"key":"BFleu2017138_CR19","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","volume":"127","author":"A Jakubowiak","year":"2016","unstructured":"Jakubowiak A, Offidani M, Pegourie B, De La Rubia J, Garderet L, Laribi K et al. Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM. Blood 2016; 127: 2833\u20132840.","journal-title":"Blood"},{"key":"BFleu2017138_CR20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195\u20131206.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2017138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2017138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:35:15Z","timestamp":1648733715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFleu2017138"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.138","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"assertion":[{"value":"1 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SKK: research funding (Abbvie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda) and honoraria (Skyline Diagnostics); MAD: honoraria (Celgene, Janssen, Amgen and Takeda); ET: research funding and honoraria (Amgen, Celgene and Janssen), and honoraria (Novartis, GSK, Bristol Myers Squibb and Takeda); HG: research funding, advisory board and honoraria (Janssen, Celgene, Novartis and BMS), research funding and honoraria (Chugai), and advisory boards (Amgen and Takeda); JH: consultancy, honoraria and advisory board (Amgen), honoraria and advisory board (Janssen, Celgene and Novartis), honoraria (Bristol Myers Squibb) and research funding (Sanofi); MB: speakers bureau and advisory board (Celgene, Janssen-Cilag, Amgen, Novartis, Takeda and Bristol Myers Squibb); MA: speakers bureau (Janssen); AO: advisory board and consultancy (Amgen and Janssen), and consultancy (Takeda); MVM: honoraria and advisory board (Janssen, Celgene, Takeda and Amgen); RV: research support and consultancy\/honoraria (Amgen, Celgene and Takeda), and consultancy\/honoraria (Bristol Myers Squibb, Janssen, Karyopham and Abbvie); H Lokhorst: research funding and advisory board (Janssen), and research funding (Genmab); NvdD: research funding (Janssen, Celgene, Amgen and BMS) and advisory board (Janssen, Celgene, Amgen, BMS and Novartis); TM: research funding (Amgen and Celgene); MH: advisory board (Celgene, Janssen, Amgen and Takeda); H Ludwig: speakers bureau (Celgene, Takeda, Amgen and Janssen-Cilag), advisory board (Celgene, Amgen, Janssen-Cilag, AbbVie and Bristol Myers Squibb) and research funding (Takeda and Amgen); MD: consultancy (Amgen, Bristol Myers Squibb, Celgene, Janssen and Takeda) and research funding (Celgene and Janssen); U-HM: advisory board (Amgen and Takeda) and honoraria (Amgen, Celgene, Takeda, Mundipharma, Janssen and Novartis); SZU: advisory board (Amgen, Celgene and Skyline Diagnostics), speakers bureau (Amgen, Celgene and Takeda) and research funding (Amgen, Celgene, Janssen, Sanofi, Pharmacyclics, Array Biopharma and Takeda); PM: advisory board (Celgene, Takeda, Janssen, Novartis and Amgen); LR: honoraria (Janssen and Celgene); all the other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}